Cornelius Dodoo

Dr. Cornelius Dodoo

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2017 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
CDCornelius Dodoo
Cornelius Dodoo
JWJie Wang
Jie Wang
ABAbdul W. Basit
Abdul W. Basit
PSPaul Stapleton
Paul Stapleton
Simon GaisfordSimon Gaisford
Simon Gaisford

1 January 2019 in International Journal of Pharmaceutics
Verified
Journal Article
Open access
FMFrédéric Moens
Frédéric Moens
PAPieter Van Den Abbeele
Pieter Van Den Abbeele
ABAbdul W. Basit
Abdul W. Basit
CDCornelius Dodoo
Cornelius Dodoo
RCRangan Chatterjee
Rangan Chatterjee
Simon GaisfordSimon Gaisford
Simon Gaisford
Poorly formulated probiotic supplements intended for oral administration often fail to protect bacteria from the challenges of human digestion, meaning bacteria do not reach the small intestine in a viable state. As a result, the ability of probiotics to influence the human gut microbiota has not been proven. Here we show how (i) considered formulation of an aqueous probiotic suspension can facilitate delivery of viable probiotic bacteria to the gut and (ii) quantitate the effect of colonisation and proliferation of specific probiotic species on the human gut microbiota, using an in-vitro gut model. Our data revealed immediate colonisation and growth of three probiotic species in the luminal and mucosal compartments of the proximal and distal colon, and growth of a fourth species in the luminal proximal colon, leading to higher proximal and distal colonic lactate concentrations. The lactate stimulated growth of lactate-consuming bacteria, altering the bacterial diversity of the microbiota and resulting in increased short-chain fatty acid production, especially butyrate. Additionally, an immunomodulatory effect of the probiotics was seen; production of anti-inflammatory cytokines (IL-6 and IL-10) was increased and production of inflammatory chemokines (MCP-1, CXCL 10 and IL-8.) was reduced. The results indicate that the probiotic species alone do not result in a clinical effect; rather, they facilitate modulation of the gut microbiota composition and metabolic activity thereby influencing the immune response.

17 September 2021 in Antibiotics
Verified
Journal Article
Open access
PDF file
NDNikki D’arcy
Nikki D’arcy
Diane Ashiru-OredopeDiane Ashiru-Oredope
Diane Ashiru-Oredope
OOOmotayo Olaoye
Omotayo Olaoye
DADaniel Afriyie
Daniel Afriyie
ZAZainab Akello
Zainab Akello
AVAnn Versporten
Ann Versporten
Antimicrobial resistance (AMR) remains an important global public health issue with antimicrobial misuse and overuse being one of the main drivers. The Global Point Prevalence Survey (G-PPS) of Antimicrobial Consumption and Resistance assesses the prevalence and the quality of antimicrobial prescriptions across hospitals globally. G-PPS was carried out at 17 hospitals across Ghana, Uganda, Zambia and Tanzania. The overall prevalence of antimicrobial use was 50% (30–57%), with most antibiotics prescribed belonging to the WHO ‘Access’ and ‘Watch’ categories. No ‘Reserve’ category of antibiotics was prescribed across the study sites while antimicrobials belonging to the ‘Not Recommended’ group were prescribed infrequently. Antimicrobials were most often prescribed for prophylaxis for obstetric or gynaecological surgery, making up between 12 and 18% of total prescriptions across all countries. The most prescribed therapeutic subgroup of antimicrobials was ‘Antibacterials for systemic use’. As a result of the programme, PPS data are now readily available for the first time in the hospitals, strengthening the global commitment to improved antimicrobial surveillance. Antimicrobial stewardship interventions developed included the formation of AMS committees, the provision of training and the preparation of new AMS guidelines. Other common interventions included the presentation of findings to clinicians for increased awareness, and the promotion of a multi-disciplinary approach to successful AMS programmes. Repeat PPS would be necessary to continually monitor the impact of interventions implemented. Broader participation is also encouraged to strengthen the evidence base.

1 May 2018 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
PVParameswara Rao Vuddanda
Parameswara Rao Vuddanda
MAMustafa Alomari
Mustafa Alomari
CDCornelius Dodoo
Cornelius Dodoo
STSarah J. Trenfield
Sarah J. Trenfield
SVSitaram Velaga
Sitaram Velaga
Simon GaisfordSimon Gaisford
Simon Gaisford

1 October 2018 in International Journal of Pharmaceutics
Verified
Journal Article
Open access
MAMustafa Alomari
Mustafa Alomari
PVParameswara R. Vuddanda
Parameswara R. Vuddanda
STSarah J. Trenfield
Sarah J. Trenfield
CDCornelius Dodoo
Cornelius Dodoo
SVSitaram Velaga
Sitaram Velaga
Simon GaisfordSimon Gaisford
Simon Gaisford
Hypothyroidism is a chronic and debilitating disease that is estimated to affect 3% of the general population. Clinical experience has highlighted the synergistic value of combining triiodothyronine (T3) and thyroxine (T4) for persistent or recurrent symptoms. However, thus far a platform that enables the simultaneous and independent dosing of more than one drug for oral administration has not been developed. Thermal inkjet (TIJ) 2D printing is a potential solution to enable the dual deposition of T3 and T4 onto orodispersible films (ODFs) for therapy personalisation. In this study, a two-cartridge TIJ printer was modified such that it could print separate solutions of T3 and T4. Dose adjustments were achieved by printing solutions adjacent to each other, enabling therapeutic T3 (15-50 μg) and T4 dosages (60-180 μg) to be successfully printed. Excellent linearity was observed between the theoretical and measured dose for both T3 and T4 (R2 = 0.982 and 0.985, respectively) by changing the length of the print objective (Y-value). Rapid disintegration of the ODFs was achieved (<45 s). As such, this study for the first time demonstrates the ability to produce personalised dose combinations by TIJ printing T3 and T4 onto the same substrate for oral administration.

1 February 2014 in International Journal of Pharmaceutics
Verified
Journal Article
Open access
JSJawal Said
Jawal Said
CDCornelius Dodoo
Cornelius Dodoo
MWMichael Walker
Michael Walker
DPDavid Parsons
David Parsons
PSPaul Stapleton
Paul Stapleton
Simon GaisfordSimon Gaisford
Simon Gaisford
An isothermal microcalorimetric assay was used to quantify the efficacy of a silver-containing wound dressing against two common wound pathogens, Pseudomonas aeruginosa and Staphylococcus aureus. The growth patterns of the two species were unique and varied depending on the environment in which the organisms were grown. Addition of non-silver-containing dressing altered the growth kinetics while addition of silver (contained either in a dressing or as AgNO3 solution) was seen to elicit inhibition and/or kill depending on concentration. Tests were conducted in nutrient broth and simulated wound fluid. It was found that minimum inhibitory and minimum bactericidal concentration values were higher in simulated wound fluid and under anaerobic conditions. Bioavailability of silver from the wound dressing was 35% against S. aureus in nutrient broth and 68% against both species in simulated wound fluid. The data highlight the importance of developing and conducting in vitro assays in biorelevant media.